Newpark Resources, Inc.

    Newpark Resources, Inc.

    NNYSE:NR
    7.44
    USD
    +0.08
    (+1.09%)
    109.19P/E
    Newpark Resources, Inc.
    NYSE:NR
    (New York Stock Exchange)

    Recent

    price

    7.44

    P/E

    ratio

    109.19

    div

    yld

    - -

    ROIC.AI

    2008
    2009
    2010
    2011
    2012
    2013
    2014
    2015
    2016
    2017
    2018
    2019
    2020
    2021
    2022
    2023
    TTM
    USD
    9.65
    5.54
    8.08
    10.1
    11.24
    12.25
    13.48
    8.18
    5.63
    8.75
    10.52
    9.13
    5.46
    6.72
    8.8
    8.68
    6.55
    Revenue per Share
    0.43
    -0.23
    0.47
    0.89
    0.69
    0.77
    1.23
    -1.1
    -0.49
    -0.07
    0.36
    -0.14
    -0.89
    -0.28
    -0.22
    0.17
    -1.87
    Basic EPS, GAAP
    0.07
    1
    0.36
    -0.15
    1.26
    1.79
    1.07
    1.47
    0.13
    0.45
    0.7
    0.81
    0.62
    -0.03
    -0.27
    1.16
    0.92
    Free Cash Flow per Basic Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Dividend per Share
    -0.73
    -0.97
    -0.5
    0.4
    1.1
    1.9
    3.18
    2.09
    1.56
    1.46
    1.67
    1.51
    0.58
    0.28
    0.04
    0.14
    -1.72
    Book Value per Share
    3.36
    3.27
    3.86
    4.5
    4.44
    5.42
    6.24
    5.93
    5.67
    5.55
    5.56
    5.31
    4.66
    4.27
    3.84
    4.06
    3.02
    Tangible Book Value per Share
    89
    89
    89
    90
    88
    85
    83
    83
    84
    85
    90
    90
    90
    91
    93
    86
    85
    Basic Weighted Avg Shares
    858
    490
    716
    909
    984
    1,042
    1,118
    677
    471
    748
    947
    820
    493
    615
    816
    750
    560
    Sales/Revenue/Turnover
    8.33
    -3.13
    10.9
    13.29
    9.38
    9.06
    11.68
    -3.07
    -10.7
    4.2
    6.71
    2.66
    -12.97
    -1.44
    3.47
    5.33
    6.12
    Operating Margin (%)
    27
    28
    27
    29
    33
    44
    42
    44
    38
    40
    46
    47
    45
    42
    39
    31
    30
    Depreciation Expense
    38
    -21
    42
    80
    60
    65
    102
    -91
    -41
    -6
    32
    -13
    -81
    -26
    -21
    15
    -159
    Net Income, GAAP
    33.78
    - -
    39.56
    35.89
    38.32
    35.31
    34.19
    - -
    - -
    30.37
    31.72
    - -
    - -
    - -
    - -
    42.36
    181.83
    Effective Tax Rate (%)
    4.48
    -4.2
    5.81
    8.8
    6.1
    6.27
    9.14
    -13.42
    -8.63
    -0.82
    3.41
    -1.58
    -16.38
    -4.15
    -2.55
    1.94
    -28.46
    Profit Margin (%)
    253
    163
    329
    407
    444
    406
    440
    381
    283
    347
    381
    350
    175
    238
    263
    221
    66
    Working Capital
    166
    106
    173
    190
    257
    173
    170
    171
    73
    159
    159
    180
    45
    118
    111
    76
    15
    LT Debt
    378
    368
    417
    498
    514
    581
    625
    520
    501
    547
    570
    549
    488
    462
    423
    415
    316
    Total Equity
    8.58
    - -
    8.8
    12.17
    7.82
    7.98
    10.99
    - -
    - -
    3.25
    6.11
    - -
    - -
    - -
    - -
    4.37
    8.94
    Return on Invested Capital (%)
    46.4
    - -
    57.02
    47.94
    22.64
    20.68
    27.54
    - -
    - -
    1.08
    14.23
    - -
    - -
    - -
    - -
    15.9
    44.09
    Return on Capital (%)
    - -
    - -
    - -
    - -
    91.03
    50.78
    48.14
    -41.63
    -26.81
    -4.82
    23.54
    -9.08
    -86.21
    -65.92
    -143.47
    187.38
    440.67
    Return on Common Equity (%)

    Capital Structure

    USD

    •

    in mil. unless spec.
    Mar'24
    Jun'24
    Sep'24
    ST Debt
    16
    18
    8
    LT Borrowings
    61
    40
    6
    LT Finance Leases
    17
    17
    10
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    85
    86
    86
    Market Capitalization
    617
    710
    592

    Working Capital

    USD

    •

    in mil. unless spec.
    Mar'24
    Jun'24
    Sep'24
    Total Current Assets
    348
    332
    117
    Cash, Cash Equivalents & STI
    38
    35
    43
    Accounts Receivable, Net
    160
    150
    32
    Inventories
    132
    127
    15
    Total Current Liabilities
    125
    127
    51
    Payables & Accruals
    108
    109
    43
    ST Debt
    16
    18
    8
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    -2.98%
    -6.06%
    -1.81%
    Free Cash Flow
    33.18%
    23.31%
    -499.67%
    Net Income, GAAP
    -77.06%
    25.36%
    -169.67%
    Sales/Revenue/Turnover
    1.87%
    -0.78%
    -8.09%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    176
    194
    220
    225
    816
    2023
    200
    183
    57
    168
    750
    2024
    169
    179
    44
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    0.03
    -0.08
    -0.26
    0.1
    -0.22
    2023
    0.06
    0.02
    0.09
    -0.01
    0.17
    2024
    0.09
    0.09
    -2.02
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    - -
    - -
    - -
    - -
    - -
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • gurufocus.com

      Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia

    • gurufocus.com

      TiumBio to Present Phase 2a Interim Data Highlighting Differentiated Clinical Profile for Tosposertib(TU2218) plus Pembrolizumab in First-Line R/M HNSCC at ASCO 2026

    • businesswire.com

      Newpark Resources Announces New Brand Identity, Aligning Strategic Focus on Specialty Rental Solutions for the Global Worksite Access Market

    • seekingalpha.com

      Newpark Resources, Inc. (NR) Q3 2024 Earnings Call Transcript

    • businesswire.com

      Newpark Resources Announces Third Quarter 2024 Results Conference Call and Webcast Date

    • zacks.com

      Earnings Preview: Newpark Resources (NR) Q3 Earnings Expected to Decline

    • businesswire.com

      International ID Day: Thales Stands up for a Legal and Trusted Identity for Everyone

    • businesswire.com

      SCF Acquires Newpark Fluids Systems

    • zacks.com

      Is Newpark Resources (NR) Stock Outpacing Its Oils-Energy Peers This Year?

    • zacks.com

      Wall Street Analysts Believe Newpark (NR) Could Rally 41.21%: Here's is How to Trade

    • zacks.com

      Newpark Resources (NR) Surpasses Q2 Earnings and Revenue Estimates

    • zacks.com

      What's in Store for Newpark Resources (NR) in Q2 Earnings?

    • prnewswire.com

      NEWPARK RESOURCES ANNOUNCES SECOND QUARTER 2024 RESULTS CONFERENCE CALL AND WEBCAST DATE

    • zacks.com

      Analysts Flip Bullish on These 3 Small-Cap Stocks: EZPW, NR, GPRK

    • zacks.com

      Newpark (NR) Is Attractively Priced Despite Fast-paced Momentum

    • zacks.com

      What Makes Newpark (NR) a Good Fit for 'Trend Investing'

    • zacks.com

      Newpark (NR) Shows Fast-paced Momentum But Is Still a Bargain Stock

    • zacks.com

      Newpark Resources (NR) is a Great Momentum Stock: Should You Buy?

    • zacks.com

      Does Newpark (NR) Have the Potential to Rally 39.77% as Wall Street Analysts Expect?

    • zacks.com

      Newpark (NR) is on the Move, Here's Why the Trend Could be Sustainable